Scotiabank Initiates Coverage On Myriad Genetics with Sector Outperform Rating, Announces Price Target of $29
Portfolio Pulse from Benzinga Newsdesk
Scotiabank has initiated coverage on Myriad Genetics with a Sector Outperform rating and a price target of $29.
June 27, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Scotiabank has initiated coverage on Myriad Genetics with a Sector Outperform rating and a price target of $29.
The initiation of coverage with a positive rating and a specific price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100